Profit Track 100

For more than half a century this company has been developing drugs used in the treatment of severe pain. It specialises in extended-release drugs, and says it produced the first prolonged-release morphine-sulphate tablets for cancer pain. The business has now begun branching out into medication for respiratory ailments and cardiovascular diseases. Increased sales and a reduction in R&D expenditure helped profits at this Cambridge company rise to £64.7m in 2012, under managing director Dietmar Lietner, 47.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyNapp Pharmaceutical Holdings
ActivityPharmaceuticals maker
Annual profit growth51.64%
Latest profits £000s64,686
Latest sales £000s289,291

If applicable:

* supplied by company † annualised figure ‡ profits = ebitda